Krebs Biochemicals and Industries Ltd
NSE:KREBSBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Krebs Biochemicals and Industries Ltd
Net Income (Common)
Krebs Biochemicals and Industries Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
K
|
Krebs Biochemicals and Industries Ltd
NSE:KREBSBIO
|
Net Income (Common)
-₹228.6m
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-3%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Net Income (Common)
₹55.7B
|
CAGR 3-Years
15%
|
CAGR 5-Years
21%
|
CAGR 10-Years
11%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Net Income (Common)
₹45.5B
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
10%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Net Income (Common)
₹109.2B
|
CAGR 3-Years
37%
|
CAGR 5-Years
35%
|
CAGR 10-Years
11%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Net Income (Common)
₹46.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
32%
|
CAGR 10-Years
8%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Net Income (Common)
₹22.7B
|
CAGR 3-Years
40%
|
CAGR 5-Years
13%
|
CAGR 10-Years
4%
|
|
Krebs Biochemicals and Industries Ltd
Glance View
Krebs Biochemicals & Industries Ltd. engages in the manufacture and sale of pharmaceutical ingredients and intermediates. The company is headquartered in Hyderabad, Telangana. The firm manufactures various products, such as Androstenedione for use as Steroid Intermediate, and Lovastatin and Simvastatin for anti-cholesterol. The firm's products in either pilot or research and development stages include Amlodipine, Cetirizine, Orlistat, Serratiopepetidase, Telmisartan and Phenylephrine. The firm has two manufacturing facilities one at Regadichelika, Nellore; and another one at Kothapalli Village, Kasimkota Mandal, Visakhapatnam, Andhra Pradesh, India.
See Also
What is Krebs Biochemicals and Industries Ltd's Net Income (Common)?
Net Income (Common)
-228.6m
INR
Based on the financial report for Dec 31, 2025, Krebs Biochemicals and Industries Ltd's Net Income (Common) amounts to -228.6m INR.
What is Krebs Biochemicals and Industries Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-3%
Over the last year, the Net Income (Common) growth was 7%. The average annual Net Income (Common) growth rates for Krebs Biochemicals and Industries Ltd have been 8% over the past three years , 4% over the past five years , and -3% over the past ten years .
